Probiotics for induction and maintenance of remission in inflammatory bowel disease: a meta-analysis

Chinese Journal of Gastroenterology

Volumn 20, Issue 1, 2015, Pages 29-35

  Wang, Xiaoteng ^a   Dai, Jinfeng ^a   Lü, Bin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Inflammatory bowel disease; Meta analysis; Probiotics; Randomized controlled trial

Indexed keywords

MESALAZINE; PLACEBO; PROBIOTIC AGENT;

ARTICLE; CROHN DISEASE; DRUG EFFECT; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; SIDE EFFECT; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 84926138098     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1008-7125.2015.01.008     Document Type: Article

References (27)

1. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice[J]. Nature, 2012, 487 (7405): 104-108.
2. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2011, 17 (1): 179-184.
3. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD[J]. Nat Rev Gastroenterol Hepatol, 2012, 9 (10): 599-608.
4. Higgins JP, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011][S/OL]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Matthes H, Krummenerl T, Giensch M, et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)[J]. BMC Complement Altern Med, 2010, 10: 13.
6. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis[J]. Am J Gastroenterol, 2009, 104 (2): 437-443.
7. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis[J]. Med Sci Monit, 2004, 10 (11): PI126-PI131.
8. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis[J]. Aliment Pharmacol Ther, 2012, 35 (3): 327-334.
9. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2009, 7 (11): 1202-1209, 1209.e1.
10. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study[J]. Am J Gastroenterol, 2010, 105 (10): 2218-2227.
11. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis[J]. Aliment Pharmacol Ther, 2004, 20 (10): 1133-1141.
12. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial[J]. Gut, 2005, 54 (2): 242-249.
13. Petersen AM, Mirsepasi H, Halkjær SI, et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial[J]. J Crohns Colitis, 2014, 8 (11): 1498-1505.
14. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial[J]. Lancet, 1999, 354 (9179): 635-639.
15. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis[J]. Aliment Pharmacol Ther, 1997, 11 (5): 853-858.
16. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis[J]. Aliment Pharmacol Ther, 2006, 23 (11): 1567-1574.
17. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine[J]. Gut, 2004, 53 (11): 1617-1623.
18. Wildt S, Nordgaard I, Hansen U, et al. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis[J]. J Crohns Colitis, 2011, 5 (2): 115-121.
19. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?[J]. J Clin Gastroenterol, 1997, 25 (4): 653-658.
20. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease[J]. BMC Gastroenterol, 2004, 4: 5.
21. Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease[J]. Aliment Pharmacol Ther, 2010, 32 (7): 872-883.
22. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease[J]. Inflamm Bowel Dis, 2005, 11 (9): 833-839.
23. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG[J]. Gut, 2002, 51 (3): 405-409.
24. Marteau P, Lémann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial[J]. Gut, 2006, 55 (6): 842-847.
25. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection[J]. Inflamm Bowel Dis, 2007, 13 (2): 135-142.
26. Bourreille A, Cadiot G, Le Dreau G, et al; FLORABEST Study Group. Saccharomyces boulardii does not prevent relapse of Crohn's disease[J]. Clin Gastroenterol Hepatol, 2013, 11 (8): 982-987.
27. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation[J]. Inflamm Bowel Dis, 2007, 13 (9): 1153-1164.